FII & DII Stake Increases in This Pharma Major As Company Reports 55% Revenue Growth in Q1FY27; India Business Delivers 19% Organic Growth

On Thursday, Indian equity benchmark indices traded higher, with the benchmark Nifty 50 index rising 66.95 points, or 0.28 per cent, to 24,317.15. Amid the positive market sentiment, Torrent Pharmaceuticals share price slipped 0.13 per cent to Rs 4,872.10 despite the company reporting strong Q1 FY27 results.

Torrent Pharmaceuticals Q1 FY27 Results

Torrent Pharmaceuticals reported a strong financial performance for the quarter ended June 30, 2026. On a consolidated basis, revenue from operations increased 55 per cent YoY to Rs 4,921 crore from Rs 3,178 crore in the corresponding quarter last year and rose 17.2 per cent QoQ from Rs 4,197 crore in Q4 FY26.

Profit before Tax (PBT) declined 0.7 per cent YoY to Rs 733 crore from Rs 738 crore but increased 38.6 per cent QoQ from Rs 529 crore. Profit after tax (PAT) increased 3.3 per cent YoY to Rs 566 crore from Rs 548 crore and surged 55.5 per cent QoQ from Rs 364 crore. Earnings per share (EPS) stood at Rs 14.87, compared with Rs 16.19 in Q1 FY26.

Operational Performance

The company reported Operating EBITDA (before exceptional items) of Rs 1,664 crore, up 61 per cent YoY, while the Operating EBITDA margin improved to 33.8 per cent from 32.5 per cent a year ago. Gross profit increased 56 per cent to Rs 3,758 crore, with the gross margin expanding to 76.4 per cent. R&D expenditure stood at Rs 172 crore, representing around 4 per cent of revenue.

Business Highlights

The base business generated revenue of Rs 3,720 crore, registering 17 per cent YoY growth, while Operating EBITDA increased 20 per cent to Rs 1,240 crore with a margin of 33.3 per cent.

The India business delivered a record 19 per cent organic revenue growth to Rs 2,157 crore, significantly outperforming the Indian Pharmaceutical Market (IPM) growth of 12 per cent. Torrent also became the No. 1 player in the Indian cardiac market, while its generic Semaglutide captured a 36 per cent market share during Q1 FY27.

Internationally, Brazil revenue grew 27 per cent, US revenue increased 36 per cent, while Germany revenue rose 3 per cent during the quarter.
Also Read - Balkrishna Industries Reports 57% YoY PAT Growth In Q1FY27; Board Declares 200% Interim Dividend; Share Price Jumps 10%

JB Business Performance

The company's JB Business reported 10 per cent YoY revenue growth to Rs 1,201 crore. Operating EBITDA increased 34 per cent to Rs 424 crore, while the EBITDA margin expanded to 35.3 per cent.

Within the segment, the India prescription business grew 13 per cent, while the international business, comprising the US, emerging markets and CDMO operations, increased 12 per cent. The CDMO business posted 27 per cent revenue growth during the quarter.

The company's shareholding pattern also resulted in increased institutional interest during the July 2026 quarter. FII holding rose to 17.97 per cent from 15.44 per cent in June 2026, while DII holding increased to 12.77 per cent from 9.73 per cent during the same period.

About Torrent Pharmaceuticals 

Torrent Pharmaceuticals Limited is the flagship pharmaceutical company of the Torrent Group and ranks among the top five pharmaceutical companies in India. The company has a presence in more than 50 countries, operates 16 manufacturing facilities, including eight USFDA-approved plants, and has a strong focus on chronic and specialty therapies across cardiovascular, gastrointestinal, central nervous system, pain management and dermatology segments.

What are your views on Torrent Pharmaceuticals' Q1 FY27 performance? Share your thoughts in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.